Indaptus Therapeutics Inc(INDP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.97 | Insider Own | 96.45% | Shs Outstand | 133.2M | Perf Week | 4.91% |
| Market Cap | 0.46B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.5M | Perf Month | -20.69% |
| Enterprise Value | 0.45B | PEG | - | EPS next Q | - | Inst Own | 0.25% | Short Float | 15.06% | Perf Quarter | 14.56% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | 257.29% | Short Ratio | 0.93 | Perf Half Y | -5.08% |
| Sales | 0.00B | P/B | 35.03 | EPS next 5Y | - | ROA | -163.84% | Short Interest | 0.82M | Perf YTD | 2.75% |
| Book/sh | 0.09 | P/C | 39.76 | EPS past 3/5Y | 23.68% 36.34% | ROE | -318.04% | 52W High | -49.83% ($5.96) | Perf Year | -13.33% |
| Cash/sh | 0.08 | P/FCF | - | Sales past 3/5Y | - | ROIC | -135.62% | 52W Low | 225% ($0.92) | Perf 3Y | -95.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 81.43% | Gross Margin | - | Volatility(W/M) | 12.64% 15.46% | Perf 5Y | -98.51% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.39 | Perf 10Y | -99.97% |
| Dividend Ex-Date | - | Quick Ratio | 19.48 | EPS Q/Q | 99.83% | Profit Margin | - | RSI (14) | 55.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.48 | Sales Q/Q | - | SMA20 | 12.01% ($2.67) | Beta | 1.04 | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 30.95% ($2.28) | Rel Volume | 0.25 | Prev Close | $3.16 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 30.98% ($2.28) | Avg Volume(3M) | 0.88M | Price | $2.99 |
| IPO | 2012/12/26 | Option/Short | No/Yes | Trades | 1022 | Volume | 224,186 | Change | -5.38% |
🧬 A clinical-stage biotech company developing next-generation immuno-oncology therapies that activate the immune system to attack tumors. Its lead pipeline candidate, Decoy20, is based on an attenuated bacterial platform and is focused on early-stage clinical development targeting advanced solid tumors.
Over the past 1 year, roughly in the middle
50% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
INDP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #226 of 594 in the industry
Based on market cap of $459M.
DMAC#224 DiaMedica Therapeutics Inc $465M PER - 
OVID#225 Ovid Therapeutics Inc $463M PER - INDP#226 Indaptus Therapeutics Inc $459M PER - 
MPLT#227 MapLight Therapeutics Inc $459M PER - 
AGMB#228 AgomAb Therapeutics NV ADR $456M PER - 
FAQ
What kind of company is INDP?
INDP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INDP?
The market cap of INDP is approximately $459M, ranking 3,229 within its sector.
What is the 52-week high and low for INDP?
INDP has recorded a 52-week high of $5.96 and a low of $0.92.
